Adenovirus E1B 55-kilodalton protein targets SMARCAL1 for degradation during infection and modulates cellular DNA replication

Nazeer, Reshma; Qashqari, Fadi; Albalawi, Abeer; Piberger, Ann Liza; Tilotta, Maria; Read, Martin; Hu, Siyuan; Davis, Simon; McCabe, Christopher; Petermann, Eva; Turnell, Andrew

DOI: 10.1128/JVI.00402-19

License:
None: All rights reserved

Document Version
Peer reviewed version

Citation for published version (Harvard):

Link to publication on Research at Birmingham portal

Publisher Rights Statement:
Checked for eligibility: 09/05/2019

This document is the Author Accepted Manuscript version of a published work which appears in its final form in Journal of virology, copyright © 2019 American Society for Microbiology. The final Version of Record can be found at: https://doi.org/10.1128/JVI.00402-19

General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

• Users may freely distribute the URL that is used to identify this publication.
• Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
• Users may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
• Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Download date: 06. Apr. 2021
Adenovirus E1B-55K targets SMARCAL1 for degradation during infection and modulates cellular DNA replication

Reshma Nazeer1, Fadi S. I. Qashqari1, Abeer S. Albalawi1, Ann Liza Piberger1, Maria Teresa Tilotta1, Martin L. Read2, Siyuan Hu1,3, Simon Davis1,4, Christopher J. McCabe2, Eva Petermann1 and Andrew S. Turnell1*

1Institute of Cancer & Genomic Sciences
2Institute of Metabolism & Systems Research
College of Medical and Dental Sciences
The University of Birmingham
United Kingdom
B15 2TT

3University of Glasgow Centre for Virus Research
Glasgow
United Kingdom
G61 1QH

4Target Discovery Institute
Nuffield Department of Medicine
University of Oxford
United Kingdom
OX3 7FZ

*Author for correspondence: Andrew S Turnell
Telephone: +44-121-414-9164
e-mail: A.S.Turnell@bham.ac.uk

Running title: Adenovirus and ATR signalling pathways

Abstract: 182 words
Main text: 5966 words
Abstract

Here we show that the cellular DNA replication protein and ATR substrate, SMARCAL1, is recruited to viral replication centres early during adenovirus infection and is then targeted in an E1B-55K/E4orf6 and Cullin Ring Ligase-dependent manner for proteasomal degradation. In this regard we have determined that SMARCAL1 is phosphorylated at S123, S129 and S173 early during infection, in an ATR- and CDK-dependent manner, and that pharmacological inhibition of ATR and CDK activities attenuates SMARCAL1 degradation. SMARCAL1 recruitment to viral replication centres was shown to be largely dependent upon SMARCAL1 association with the RPA complex, whilst Ad-induced SMARCAL1 phosphorylation also contributed towards SMARCAL1 recruitment to viral replication centres, albeit to a limited extent. SMARCAL1 was found associated with E1B-55K in adenovirus E1-transformed cells. Consistent with its ability to target SMARCAL1 we determined that E1B-55K modulates cellular DNA replication. As such, E1B-55K expression initially enhances cellular DNA replication fork-speed but ultimately leads to increased replication fork stalling and the attenuation of cellular DNA replication. We propose therefore, that adenovirus targets SMARCAL1 for degradation during infection to inhibit cellular DNA replication and promote viral replication.
Importance

Viruses have evolved to inhibit cellular DNA damage response pathways that possess antiviral activities and utilize DNA damage response pathways that possess pro-viral activities. Adenovirus has evolved, primarily, to inhibit DNA damage response pathways by engaging with the ubiquitin-proteasome system and promoting the degradation of key cellular proteins. Adenovirus regulates, differentially, ATR DNA damage response signalling pathways during infection. The cellular, adenovirus E1B-55K binding protein, E1B-AP5, participates in ATR signalling pathways activated during infection, whilst adenovirus 12 E4orf6 negates Chk1 activation by promoting the proteasome-dependent degradation of ATR activator, TOPBP1. The studies detailed herein indicate that adenovirus utilises ATR kinase and CDKs during infection to promote the degradation of SMARCAL1 to attenuate normal cellular DNA replication. These studies further our understanding of the relationship between adenovirus and DNA damage and cell cycle signalling pathways during infection and establish new roles for E1B-55K in the modulation of cellular DNA replication.
Introduction

Cellular DNA damage response (DDR) signalling pathways coordinated by the phosphoinositide 3-kinase (PI3K)-like kinase proteins Ataxia Telangiectasia Mutated (ATM), ATM-Rad3-related gene (ATR) and DNA-dependent protein kinase (DNA-PK) are often targeted by viruses during infection in order to facilitate viral replication (1, 2). As such, viruses often exploit the ubiquitin-proteasome system to inhibit DDR pathway components that possess anti-viral activities, and utilize DDR pathway components that possess pro-viral activities (1, 3). In this regard adenovirus (Ad) types from all groups have evolved, almost exclusively, to inhibit DDR pathways during infection. Early work determined that Ad5 E1B-55K and E4orf6 assemble an Ad ubiquitin (Ub) ligase complex consisting of Cullin Ring Ligase 5 (CRL5), Elongin B, Elongin C and Rbx1 that was capable of promoting the specific degradation of the tumour suppressor gene product, p53 during infection (4, 5). In this regard BC box motifs within E4orf6 served to recruit CRL5 through association with Elongins B and C, whereas E1B-55K served to recruit p53 to the Ad Ub ligase through interaction with E4orf6 (6). Later studies indicated that group A viruses, such as Ad12, utilized CRL2 to promote the degradation of p53 during infection (7, 8).

The Ad Ub ligase was subsequently shown to inhibit the ATM-coordinated response to viral infection by promoting the degradation of MRE11 and BLM to ensure that viral genome processing, resection, recombination and concatenation are all negated (9, 10). Adenovirus was also shown to inhibit non-homologous end-joining pathways coordinated by DNA-PK by targeting DNA ligase IV for Ad Ub ligase-mediated degradation that also served to prevent viral genome concatenation (11). The Ad Ub ligase has also been shown to promote the degradation of cellular proteins not involved in DDR signalling but do, nevertheless, possess anti-viral activities. As such cellular proteins involved in cell signalling, cell adhesion and...
cell-contacts such as integrin α3, ALCAM, EPHA2 and PTPRF are all targeted for degradation during infection (12, 13). E1B-55K can also, in isolation, promote the proteasomal-mediated degradation of Daxx, a component of PML nuclear bodies and transcriptional regulator that has antiviral activities (14), whilst Ad E4orf3 which possesses inherent SUMO ligase activity can target cellular proteins such as TIF1γ and TFII-I for SUMO-targeted ubiquitin ligase (STUbL) -mediated degradation during infection (15-17).

The ATR kinase serves specifically to regulate pathways that control DNA replication in response to replication stress (18). ATR is an essential gene; hypomorphic mutations cause Seckel syndrome that is a pleiotropic disease characterized primarily by growth retardation and microcephaly (18). ATR signalling pathways are targeted, specifically, during Ad infection. It has long been known that the single-stranded (ss)DNA-binding protein complex, RPA, which participates in ATR signalling pathways through its association with ssDNA during cellular DNA replication and following resection at double-stranded (ds)DNA breaks (DSBs), is recruited to viral replication centres (VRCs) during Ad infection and presumably associates with viral ssDNA replication intermediates during genome replication (19, 20). As such RPA has often served as a surrogate marker for VRCs. More recently, a number of ATR signalling components required for ATR activation such as, ATR-interacting protein (ATRIP), and components of the RAD9-HUS1-RAD1 (9-1-1) clamp complex and Rad17, have all been shown to be recruited to VRCs following both Ad5 and Ad12 infection (19, 20). It has also been suggested that Ad5, but not Ad12, inhibits the ATR-dependent activation of Chk1 by promoting the E4orf3-dependent immobilisation of the MRE11-RAD50-NBS1 complex in nuclear tracks, whilst Ad12 E4orf6 alone associates with CRL2-Rbx1 to promote the degradation of the ATR activator, TOPBP1, and ensures that Chk1 is not activated during Ad12 infection (7, 20). It has been determined that the ATR pathway is differentially regulated during Ad infection. ATR kinase has been shown to be activated during both Ad5
and Ad12 infection and that the cellular Ad E1B-55K associated protein, E1B-AP5 (hnRNPUL1), is required for ATR activation in these circumstances (20). Indeed, E1B-AP5 was shown to be required for the ATR-dependent phosphorylation of RPA32 during infection and also contributed towards the Ad-induced phosphorylation of Smc1 and H2AX. It is not however, apparent why ATR kinase activity is not fully inactivated during Ad infection, and suggests that the virus might promote the selective ATR-dependent phosphorylation of specific substrates during infection to inhibit cellular replication and facilitate viral replication (20).

SMARCAL1 (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A-like protein 1) is a DNA-dependent ATPase and ATP-dependent annealing helicase that has the capacity to interact with both dsDNA and ssDNA through DNA-binding-domains (DBDs) within its primary structure and its interaction with the RPA complex, respectively (21-25). Bi-allelic inactivation of SMARCAL1 causes Schimke immuno-osseous dysplasia (SIOD) which is characterized by renal failure, immune deficiencies, bone growth retardation, and predisposition to different types of cancer (26). SMARCAL1 has the capacity to remodel replication forks and serves to prevent replication fork collapse and promote replication restart (21-25). As such SMARCAL1 is recruited to stalled forks through its interaction with RPA to promote fork regression and the restoration of fork structure. SMARCAL1 function is regulated by the ATR kinase; in response to replication stress ATR phosphorylates SMARCAL1 on S652 and limits its fork regression and fork processing activities (27). Indeed, when ATR is inhibited pharmacologically such that SMARCAL1 activity is not tightly regulated, uncoordinated SMARCAL1 activity promotes fork collapse (28). SMARCAL1 also participates directly in response to different types of DNA damage and is recruited in an RPA-dependent manner to DSBs that have been
processed to generate ssDNA, and serves to both stabilize replication forks, and restore fork integrity (21-25).

As our understanding of the relationship between ATR signalling pathways and adenovirus is incomplete this study sought to further our knowledge in this area. As such we determined that the ATR substrate, SMARCAL1 is phosphorylated in ATR and CDK-dependent manner and then targeted for degradation during adenovirus infection to presumably to disable its cellular activities during infection. Consistent with this notion, E1B-55K, which associates specifically with SMARCAL1, was shown to dysregulate cellular DNA replication fork speed and promote replication fork stalling. We propose therefore that adenovirus inhibits SMARCAL1 activity to effectively inactivate cellular DNA replication during infection.

Materials and Methods

Cells. A549 human lung carcinoma cells, TERT-immortalized RPE-1 (retinal pigment epithelial) cells, FlpIn T-REX U2OS cells and GP2-293 cells were grown in HEPES-modified Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich) supplemented with 8% (v/v) foetal calf serum (FCS; Sigma-Aldrich) and 2 mM L-glutamine (Sigma-Aldrich). Ad5 and Ad12 E1B-55K FlpIn T-Rex U2OS cells were maintained in HEPES-modified DMEM media in the presence of 200μg/ml Hygromycin (Life Technologies), whilst clonal RPE-1 cells that express wild-type (wt) GFP-SMARCAL1 or GFP-SMARCAL1 mutants were also maintained in HEPES-modified DMEM media in the presence of 500μg/ml G418 (Gibco). All cells were maintained at 37 ºC in a humidified 5% CO₂ atmosphere (Nuaire Autoflow).
Viruses. wt Ad5 and wt Ad12 Huie viruses were from the ATCC. Ad5 dl1520, Ad5 pm4150, Ad5 pm4154 Ad5 pm4155 and Ad12 dl620 viruses have all been described previously (15). Ad5 and Ad12 viruses were propagated on permissive human embryonic kidney (HEK) 293 cells and human embryonic retinoblastoma (HER) 3 cells, respectively, and titres determined by plaque assay on HER911, and HER3 cells, respectively. Viruses were diluted in DMEM without FCS and cells were typically infected at a multiplicity of infection (MOI) of 10. Infected cells were incubated at 37 °C with agitation every 10 minutes. After 2 hours infection, virus-containing medium was removed and replaced with fresh culture medium supplemented with 8% (v/v) FCS.

Plasmids. wt SMARCAL1 and ΔN-SMARCAL1 (lacking the N-terminal RPA-interaction domain; ΔRPA) constructs cloned into the retroviral vector pLEGFP-C1 (Clontech) were provided by Dr David Cortez. pLEGFP-C1 S123A, S129A and S173A SMARCAL1 phospho-mutants were generated using the QuikChange II XL site-directed mutagenesis kit (Agilent) and validated by Sanger sequencing. Using wt Ad5 E1B-55K and Ad12 E1B-55K cDNA templates both Ad5 and Ad12 E1B-55K were amplified by PCR, digested with BamHI and XhoI, and sub-cloned into the pcDNA5/FRT/TO plasmid for the generation of TET-inducible cell lines. Ad5 E1B-55K was amplified using the primers: Ad5 E1B55K BamHI Forward: AGGTTGGATCCATGGAGCGAAGAAACCCATCTGAG and Ad5 E1B55K XhoI Reverse: AGGTTCTCGAGTCAATCTGTATCTTCATCGCTAGA. Ad12 E1B-55K was amplified using the primers: Ad12 E1B55K BamHI Forward: TTGCAGGATCCATGGAGCGAGAAATCCCACCTGAG and Ad12 E1B55K XhoI Reverse: TTGCACTCGAGTCAGTTGTCGTCTTCATCACTTGA. Clones were validated by Sanger sequencing using the primers pcDNA5 Forward: CGCAAATGGGCGGTAGGCGTG; pcDNA5 Reverse: TAGAAGGCACAGTCGAGG; Ad5 E1B-55K seq1: GGCTACAGAGGAGGCTAGGAATCTA; Ad5 E1B-55K seq2:
Generation of clonal cell lines. FlpIn T-REX U2OS cells were grown to 90% confluence prior to transfection. The Ad5 E1B-55K and Ad12 E1B-55K pcDNA5/FRT/TO plasmids were mixed with the recombination plasmid, pOG44, in a 1:9 ratio in Opti-MEM (Life Technologies), and transfected according to the manufacturer’s instructions into FlpIn T-REX U2OS cells with the use of Lipofectamine 2000 (Life Technologies). Cells were then incubated in a CO₂-humidified incubator at 37°C for 6 hours. Following transfection cells were incubated in fresh HEPES-modified DMEM supplemented with 8% (v/v) FCS and 2mM glutamine. 24 h post-transfection cells from one plate were passaged onto four plates, and 48h post-transfection incubated with growth medium containing 200μg/ml Hygromycin (Life Technologies) for clonal selection. Cells were then fed every three days; individual colonies were ultimately selected, expanded and assessed for Ad E1B-55K expression following incubation with 0.1μg/ml doxycycline for 24h. To generate GFP-SMARCAL1 cell-lines, pLEGFP-C1 SMARCAL1 constructs were transfected in a 1:1 ratio with the pVSV envelope plasmid in the retrovirus packaging cell line, GP2-293 cells (Clontech) using Lipofectamine 2000. 72 h post-transfection, the virus-containing supernatants were collected and filtered through a 0.45 μM filter (Sartorius). Retroviral transduction of RPE-1 cells, at 20% density, was then performed. 72 h post-transduction clonal cells were selected using G418 (500 μg/ml). Individual colonies were ultimately expanded and assessed for GFP-SMARCAL1 expression.
Antibodies and inhibitors. The anti-Ad5 E1B-55K monoclonal antibody (mAb), 2A6, anti-Ad12 E1B-55K mAb, XPH9 and the anti-p53 mAb, DO-1 were all obtained as supernatant fluid from cultures of the appropriate hybridoma cell lines. The anti-SMARCAL1 (A-2) mAb was from Santa Cruz (sc-376377). Horseradish peroxidase (HRP)-conjugated secondary anti-mouse and anti-rabbit antibodies used for Western blotting were from Agilent. Secondary anti-mouse and anti-rabbit Alexa 488/594 antibodies used for immunofluorescence were from Thermo Fisher. The ATR inhibitor, AZD6738, and the CRL inhibitor, MLN4924, were purchased from Cayman chemicals, whilst the CDK inhibitor, RO-3306 was purchased from Merck Millipore.

Immunoprecipitation. Cells were harvested by washing twice in ice-cold phosphate-buffered saline and solubilized in immunoprecipitation (IP) buffer containing 20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA), 1% (v/v) Nonidet P-40, 25 mM NaF and 25 mM β-glycerophosphate. Cell lysates were then homogenized twice with 10 strokes while being kept on ice and centrifuged at 40000 rpm for 30 minutes at 4 °C. Immunoprecipitating antibodies were added to clarified supernatants at 4 °C overnight with rotation. After this time Protein G-Sepharose beads (Sigma-Aldrich) were added to all samples to capture and isolate immune complexes for 2 hours at 4 °C with rotation. The beads were then washed five times by centrifugation at 3000 rpm in ice-cold IP buffer, eluted in 30 μl of SDS-containing sample buffer and ran on SDS-PAGE gels for Western blotting.

SDS-PAGE and Western blot analysis. Whole-cell protein lysates were prepared in 9M urea, 150 mM β-mercaptoethanol, 50 mM Tris-HCl (pH 7.4). Lysates were clarified by sonication and centrifugation, and protein concentrations determined by Bradford assay (Bio-Rad). Proteins were separated by SDS–PAGE in the presence of 100 mM Tris, 100 mM...
Bicine and 0.1% (w/v) SDS. Following SDS-PAGE, proteins were electrophoretically transferred onto nitrocellulose membranes (PALL) in transfer buffer (50 mM Tris, 190 mM glycine, 20% (v/v) methanol). Membranes were then blocked in 5% (w/v) dried milk powder in TBST (Tris-buffered saline containing 0.1% (v/v) Tween-80) for 1 h at room temperature with agitation. Membranes were incubated overnight with antibodies at the appropriate dilution in TBST containing 5% (v/v) milk at 4 °C with agitation. The following day, membranes were washed four times in TBST and incubated with the appropriate HRP-conjugated secondary antibody made up in TBST containing 5% (v/v) milk at room temperature for 2 hours with agitation. Finally, membranes were washed four times in TBST and antigens were detected using enhanced chemiluminescence (ECL) reagents (Millipore) and autoradiography film (SLS).

**Microscopy.** GFP-SMARCAL1 cells were visualised using an EVOS Fluorescent digital inverted microscope. Cells for confocal microscopy were seeded on glass 12-well multi-spot microscope slides (Hendley-Essex). Following mock or Ad infection slides were fixed in 4% (w/v) paraformaldehyde in PBS then permeabilized in ice-cold acetone. Slides were then air-dried, and blocked in HINGS buffer (20% (v/v) Heat-Inactivated Normal Goat Serum, 0.2% (w/v) BSA in PBS), prior to incubation with the appropriate primary, and Alexa Fluor® secondary antibodies (Life Technologies) in HINGS buffer. Slides were then mounted in Vectashield (Vector Laboratories) containing 4′,6-diamidino-2-phenylindole (DAPI) and visualized using an LSM 510 META confocal laser scanning microscope (Carl Zeiss).

**Mass Spectrometry.** Anti-SMARCAL1 immunoprecipitates were isolated on Protein G Sepharose beads and separated upon pre-cast Novex NuPage™ 4-12% Bis-Tris Gels (Life Technologies). Protein bands were stained with colloidal Coomassie Brilliant Blue (Fisher). After washing gels in distilled water protein bands were excised and washed twice, by
agitation, with a solution containing 50 mM ammonium bicarbonate and 50% (v/v) acetonitrile for 45 min at 37°C. The excised proteins were then reduced by incubation for 1 h at 56°C in a solution containing 50 mM dithiothreitol and 50 mM ammonium bicarbonate in 10% (v/v) acetonitrile. Proteins were then incubated in an alkylating solution (200 mM iodoacetamide, 50 mM ammonium bicarbonate, and 10% (v/v) acetonitrile) for 30 min at room temperature in the dark. The protein bands were then washed three times for 15 min each at room temperature in 10% (v/v) acetonitrile/40 mM ammonium bicarbonate on a shaker, and then dried in a DNA–mini-vacuum centrifuge for 3-4 h. The dried samples were then resuspended and digested by rehydration in sequence-grade modified trypsin (Promega). An equal volume of 10% (v/v) acetonitrile/40 mM ammonium bicarbonate was then added to the protein bands and left to incubate with agitation overnight at 37°C. The resultant peptides were then analyzed using a Q Exactive™ HF Hybrid Quadrupole-Orbitrap™ Mass Spectrometer (ThermoFisher Scientific).

**DNA fibre analysis.** Cells were labelled with 25 μM CldU (Sigma-Aldrich) and 250 μM IdU (Sigma-Aldrich) for 20 min each and DNA fibre spreads prepared in 200 mM Tris-HCl pH 7.4, 50 mM EDTA, 0.5% (w/v) SDS and fixed with a 3:1 mixture of methanol.acetic acid. DNA fibre spreads were then denatured with 2.5 M HCl for 80 mins then incubated with blocking buffer (PBS + 1% (w/v) BSA + 0.1% (v/v) Tween20) for 1 h prior to incubation with rat anti-BrdU (BU1/75, Abcam ab6326, 1:250) and mouse anti-BrdU (B44, Becton Dickinson 347580, 1:500) in blocking buffer for 1 h. Fibres were then fixed with 4% (w/v) paraformaldehyde and incubated further with anti-rat AlexaFluor 555 and anti-mouse AlexaFluor 488 for 1.5 h prior to mounting and analysis on a Nikon E600 microscope with a Nikon Plan Apo 60x (1.3 NA) oil lens, a Hamamatsu digital camera (C4742-95) and the Volocity acquisition software (Perkin Elmer). Images were analyzed using ImageJ.
Results

SMARCAL1 localizes to Ad replication centres during the early stages of infection. As we and others have shown that the RPA complex and other components of ATR signalling pathways are recruited to VRCs during infection we decided initially to determine whether SMARCAL1, a known ATR substrate and RPA-binding protein, was also recruited to VRCs following infection of human A549 cells with either wild-type (wt) Ad5 or wt Ad12. Confocal microscopy revealed that like RPA complex component, RPA2, SMARCAL1 was distributed predominantly, throughout the nucleus in mock-infected, interphase A549 cells, although there did also appear to be a proportion of cytoplasmic SMARCAL1 (panels i-iii, Figure 1). Following infection with either wt Ad5, or wt Ad12, and consistent with previous studies RPA2 re-localized to VRCs (panels iv-vi, Ad5; panels vii-ix, Ad12; Figure 1). Importantly, SMARCAL1 was also recruited to VRCs, and co-localized with RPA2, following either wt Ad5, or wt Ad12 infection (panels iv-vi, Ad5; panels vii-ix, Ad12; Figure 1). Interestingly, the levels of SMARCAL1 in the Ad12-infected cells appeared to be reduced relative to mock-infected cells (cf panel ii (mock) with panel viii (Ad12), Figure 1). Taken together these data indicate that SMARCAL1 is recruited to VRCs during Ad infection.

SMARCAL1 protein levels are reduced following Ad5 and Ad12 infection. Given that the immunofluorescence studies suggested that SMARCAL1 levels were reduced following Ad12 infection (Figure 1) we next sought to determine whether absolute SMARCAL1 protein levels are affected by viral infection. To do this we infected A549 cells with either wt Ad5 or wt Ad12 and analysed SMARCAL1 protein levels at various stages post-infection. Western Blot (WB) analyses revealed that akin to p53, SMARCAL1 protein levels were reduced substantially following wt Ad5 infection (Figure 2A). WB analyses revealed that
SMARCAL1 protein levels were similarly reduced following wt Ad12 infection (Figure 2B). Interestingly, WB analyses revealed that SMARCAL1 appeared to undergo post-translational modification at early time-points post-infection, as judged by an apparent increase in its molecular weight, following infection with either wt Ad5 or wt Ad12 (Figures 2A and 2B). These data suggest that SMARCAL1 is targeted for degradation during Ad infection.

**SMARCAL1 is degraded during Ad infection in an E1B-55K/E4orf6- and CRL-dependent manner.** As E1B-55K/E4orf6 complexes and, E1B-55K, E4orf3 and E4orf6 alone have all been implicated in the targeting of cellular proteins for degradation, we next investigated which early region viral proteins were required to induce SMARCAL1 degradation during infection. To do this we infected A549 cells with wt Ad5, the E1B-55K deletion mutant, Ad5 dl1520, the E4orf3 deletion mutant, pm4150 and the Ad5 E4orf6 deletion mutant, pm4154 and then analysed SMARCAL1 protein levels at 24h and 48h post-infection (Figure 3A). In line with previous studies WB analyses revealed that p53 degradation was dependent on the expression of both E1B-55K and E4orf6 (Figure 3A). Consistent with the notion that the Ad Ub ligase was also required to promote the degradation of SMARCAL1 during infection WB analyses also revealed that SMARCAL1 degradation was dependent upon the expression of both E1B-55K and E4orf6 (Figure 3A). Consistent with a role for E1B-55K in the degradation of SMARCAL1 in Ad12-infected cells, the Ad12 E1B-55K deletion mutant, Ad12 dl620 was not as efficient as wt Ad12 in promoting the degradation of SMARCAL1 (Figure 3B).

To investigate the role for cellular CRLs in the E1B-55K/E4orf6-dependent degradation of SMARCAL1 we utilised the NEDD8-activating enzyme (NAE) inhibitor, MLN4924, which inhibits Cullin neddylation and activation (29). As MLN4924 has been shown to be effective in the low to high nM range, and moreover, has been shown to activate p53 at high nM
concentrations (29, 30), we used two different doses to assess its efficacy as a CRL inhibitor during Ad infection. We therefore infected A549 cells with \textit{wt} Ad5 or \textit{wt} Ad12, then subsequently incubated infected cells in the absence, or presence, of MLN4924 and analysed SMARCAL1 protein levels at 24h and 48h post-infection (Figure 3C and 3D). WB analyses revealed that 500nM MLN4924 reduced markedly the ability of \textit{wt} Ad5 and \textit{wt} Ad12 to promote SMARCAL1 degradation (cf lanes 3 and 4 with lanes 11 and 12, Figures 3C and 3D). As noted in other studies MLN4924 treatment, in the absence of infection promoted p53 stabilisation, and consistent with other reports limited p53 degradation following Ad infection (30; cf lanes 1 and 2 with lanes 5 and 6 and 9 and 10, Figures 3C and 3D). Pertinently however, MLN4924 treatment did not affect the levels of SMARCAL1 in mock-infected cells (cf lanes 1 and 2 with lanes 5 and 6 and 9 and 10, Figures 3C and 3D). Taken together these data suggest that E1B-55K/E4orf6 recruit cellular CRLs to promote the degradation of SMARCAL1 during Ad infection.

\textbf{SMARCAL1 is phosphorylated in the early stages of Ad5 and Ad12 infection.} As ATR kinase is known to be activated following Ad infection and SMARCAL1 migration on SDS-PAGE was retarded following infection we next investigated whether SMARCAL1 was phosphorylated in response to Ad infection. To do this we first infected A549 cells with either \textit{wt} Ad5 or \textit{wt} Ad12 then immunoprecipitated SMARCAL1 from mock-infected or Ad-infected cells with an anti-SMARCAL1 antibody. Immunoprecipitates were then either left untreated or treated with λ-phosphatase prior to investigating the migratory properties of SMARCAL1 on SDS-PAGE. Consistent with the notion that SMARCAL1 is phosphorylated following Ad infection, WB analyses revealed that when anti-SMARCAL1 immunoprecipitates from Ad-infected cells were treated with λ-phosphatase the migration of SMARCAL1 was increased, relative to untreated samples, and comparable to the migration of SMARCAL1 from mock-infected cells (cf lanes 6 and 8 with lane 1, Figure 4A).
Treatment with the NAE inhibitor promoted limited phosphorylation of SMARCAL1 (cf lanes 3 and 4, Figure 4A). To determine which SMARCAL1 residues were phosphorylated following Ad infection we immunoprecipitated SMARCAL1 from mock, Ad5 and Ad12 -infected A549 cells and following SDS-PAGE, and gel-slice processing we subjected isolated tryptic peptides to tandem array mass spectrometry (MS/MS). MS analyses revealed that SMARCAL1 was phosphorylated at three major sites following both Ad5 and Ad12 infection: S123, S129 and S173 (Figure 4B). S123 and S129 formed part of a minimal CDK consensus phosphorylation motif, SP, whilst S173 formed part of an ATR consensus phosphorylation motif, SQE. Sequence homology searches revealed that these residues were conserved amongst primates, but less well conserved for lower mammals (Figure 4C).

**Pharmacological inhibition of ATR kinase and CDK activities limits SMARCAL1 degradation following Ad5 and Ad12 infection.** Given that SMARCAL1 phosphorylation precedes its degradation following Ad infection we next investigated whether the ATR and CDK -dependent phosphorylation of SMARCAL1 during Ad infection was an essential prerequisite for the Ad-induced degradation of SMARCAL1. To do this we studied the effects of the selective ATR kinase inhibitor, AZD6738, and the CDK inhibitor, RO-3306, on the ability of both wt Ad5 and wt Ad12 to induce the degradation of SMARCAL1. Initially, therefore, A549 cells were either mock-infected or infected with wt Ad5 or wt Ad12, and then incubated in the absence or presence of AZD6738 for specific times post-infection. WB analyses revealed that treatment of A549 cells with AZD6738 reduced modestly the ability of wt Ad5 to promote the degradation of SMARCAL1 (cf lanes 7 and 8 with lanes 5 and 6, Figure 5A). Interestingly, however, the effect of AZD6738 treatment on the ability of wt Ad12 to promote SMARCAL1 degradation was much more dramatic; the ATR kinase inhibitor reduced appreciably the ability of wt Ad12 to stimulate SMARCAL1 degradation during infection, with no observable degradation at 24h post-infection (cf lanes 7 and 8 with...
lanes 5 and 6, Figure 5B). To establish whether CDKs cooperate with ATR to promote SMARCAL1 degradation following Ad infection we infected A549 cells with either wt Ad5, or wt Ad12 then incubated infected cells in the absence, or presence, of AZD6738 and RO-3306 for specific times post-infection. WB analyses revealed that the use of both inhibitors reduced substantially the ability of wt Ad5 to promote the degradation of SMARCAL1, particularly at 48h post-infection (cf lanes 5 and 6 with lanes 7 and 8, Figure 5C). Similarly, the combined effects of AZD6738 and RO-3306 were to almost abate entirely the ability of wt Ad12 to induce the degradation of SMARCAL1 (cf lanes 5 and 6 with lanes 7 and 8, Figure 5D). Taken together these data suggest strongly that the combined ATR kinase and CDK-dependent phosphorylation of SMARCAL1 facilitate the E1B-55K/E4orf6-dependent degradation of SMARCAL1 during Ad infection. As such, these studies are important in establishing that Ad can activate, and then utilise, cellular kinases during infection to promote viral replication.

SMARCAL1 recruitment to VRCs is largely dependent upon its association with the RPA complex but is also regulated by ATR and CDK-dependent phosphorylation. To explore in more detail the factors that modulate the recruitment of SMARCAL1 to VRCs during Ad infection we generated a phosphorylation-defective GFP-SMARCAL1-ΔP (S123A, S129A and S173A) mutant in order to ablate the ATR, and CDK, -dependent phosphorylation of SMARCAL1 in response to Ad infection, and utilised a GFP-SMARCAL1-ΔRPA mutant that is unable to bind the RPA complex (21). We then generated clonal, RPE-1 cell lines that expressed constitutively, either GFP alone, wt GFP-SMARCAL1, GFP-SMARCAL1-ΔP or GFP-SMARCAL1-ΔRPA. Then, to investigate the role SMARCAL1 phosphorylation and the RPA complex play in SMARCAL1 recruitment to VRCs we infected these cell lines with either wt Ad5 or wt Ad12, and analysed GFP-SMARCAL1 cellular distribution throughout the infection process. Pertinently, Ad infection
of GFP alone RPE-1 cells had no effect upon the pan-cellular distribution of GFP (data not shown). In mock-infected RPE-1 cells wt GFP-SMARCAL1, GFP-SMARCAL1-ΔP and GFP-SMARCAL1-ΔRPA were distributed evenly throughout the nucleus (panels i-iii, Figure 6A). Following infection of RPE-1 cells with either wt Ad5, or wt Ad12, wt GFP-SMARCAL1 was re-distributed to VRCs (panels iv and vii respectively, Figure 6A).

Interestingly, the ability of both wt Ad5 and wt Ad12 to promote the recruitment of the GFP-SMARCAL1-ΔP mutant to VRCs, relative to wt GFP-SMARCAL1 was reduced significantly, but only by one-third (panels v and viii, Figure 6A; Figure 6B). Moreover, the ability of both wt Ad5 and wt Ad12 to promote the recruitment of GFP-SMARCAL1-ΔRPA, relative to wt GFP-SMARCAL1, was also reduced significantly, by approximately two-thirds (panels vi and ix, Figure 6A; Figure 6B). Taken together, these data suggest that the RPA complex plays a major role in the recruitment of SMARCAL1 to VRCs during Ad infection, whilst the ATR- and CDK- dependent phosphorylation of SMARCAL1, although not essential, also contributes towards SMARCAL1 recruitment to VRCs following Ad infection.

Given that ATR and CDK inhibitors restricted the ability of both wt Ad5 and wt Ad12 to promote SMARCAL1 degradation during infection, we also wished to use this experimental system to explore the specific roles of S123, S129 and S173 phosphorylation in the Ad-mediated degradation of SMARCAL1. Unfortunately, Ad infection of RPE-1 cells that constitutively expressed GFP-SMARCAL1 species resulted in the enhanced expression of GFP-SMARCAL1 species, probably as a result of E1A transactivation of the CMV promoter driving the expression of GFP-SMARCAL1 species (data not shown). As such we were not able to determine the individual contribution of specific SMARCAL1 phosphorylation sites in the Ad-induced degradation process.
Ad5 and Ad12 E1B-55K associate with SMARCAL1 in Ad-transformed cells. As E1B-55K has previously been shown to function as a substrate adaptor in the recruitment of cellular proteins, such as p53 and MRE11, for CRL-dependent degradation during infection, we next investigated whether E1B-55K also served as an adaptor for SMARCAL1 and could be found associated with SMARCAL1 in Ad-transformed cells. To investigate whether Ad5 and Ad12 E1B-55K were found associated with SMARCAL1 in Ad-transformed cells we performed reciprocal co-immunoprecipitation studies using Ad5 HEK 293 cells and Ad12 HER2 cells. Consistent with the notion that E1B-55K and SMARCAL1 associate in vivo, anti-E1B-55K antibodies co-immunoprecipitated SMARCAL1, and anti-SMARCAL1 antibodies co-immunoprecipitated E1B-55K, from both Ad5 HEK 293 cells and Ad12 HER2 cells (Figure 7A and 7B, respectively). Given that p53 is a known E1B-55K-interacting protein, we performed reciprocal p53 and E1B-55K co-immunoprecipitation studies to validate the approach taken (Figure 7A and 7B, respectively).

Generation of Ad5 and Ad12 E1B-55K FlpIn T-REX U2OS clonal cell lines. As we have shown that Ad E1B-55K can associate with SMARCAL1 in Ad-transformed cells (Figure 7) we wished to investigate the specific effects of E1B-55K expression, in isolation, upon SMARCAL1 function. To begin to do this we first generated clonal TET-inducible Ad5 and Ad12 E1B-55K FlpIn U2OS cells that upon induction with the tetracycline analogue, doxycycline, expressed Ad5 and Ad12 E1B-55K (Figure 8). Consistent with the role for Ad E1B-55K in the stabilization of the p53 tumour suppressor, p53 protein levels were also increased following both Ad5 and Ad12 E1B-55K (Figure 8). Unlike p53, the protein levels of SMARCAL1 and another E1B-55K binding partner, MRE11, were not altered appreciably, following E1B-55K expression (Figure 8). Taken together, these data demonstrate that we have generated TET-inducible Ad5 and Ad12 E1B-55K FlpIn U2OS cells that express functional E1B-55K following treatment with doxycycline.
Ad5 and Ad12 E1B-55K dysregulate DNA fork speed during cellular DNA replication and promote replication fork collapse. It is well established that in addition to its role as a substrate adaptor in the CRL-dependent degradation of p53 during Ad infection, E1B-55K can, in isolation, also inhibit the transactivation properties of p53 (31). As SMARCAL1 possesses the inherent ability to prevent replication fork collapse in unperturbed S-phase and, in response to agents that promote replication stress, promote replication fork restart after fork collapse we wished to establish whether Ad E1B-55K could also modulate the cellular functions of SMARCAL1. To measure the effects of Ad E1B-55K expression upon replication fork speed during unperturbed S-phase we utilised the DNA fibre assay. To do this we pulse-labelled FlPIn U2OS cells (+/- Ad5 or Ad12 E1B-55K expression) successively with the thymidine analogues, CldU and IdU for 20 minutes each to label DNA at replication forks. DNA fibre analyses revealed that in the presence of Ad5 E1B-55K, or Ad12 E1B-55K CldU-labelled tracks of newly synthesized DNA were significantly longer, relative to mock controls, suggesting that both Ad5, and Ad12 E1B-55K expression led specifically to accelerated speeds of replication fork progression (Figures 9 A and B). Interestingly however, this accelerated fork speed at on-going DNA replication forks, in the presence of Ad E1B-55K, was not maintained when cells were subsequently labelled with IdU, such that IdU track length was comparable to cells that did not express Ad E1B-55K (Figures 9 A and B). As an increased CldU/IdU ratio can be indicative of fork stalling or collapse (32) we next quantified the effects of Ad E1B-55K expression on replication fork collapse. Consistent with the notion that the Ad E1B-55K-dependent acceleration in fork speed results in replication fork collapse, cells that expressed either Ad5 or Ad12 E1B-55K had a significantly increased number of stalled replication forks (CldU-only labelled DNA fibres) relative to cells that do not express Ad E1B-55K (Figure 9C). Taken together, these data indicate that Ad E1B-55K, can in isolation, modulate cellular DNA replication, and in consideration of the known
functions of SMARCAL1, is supportive of the notion that Ad E1B-55K interaction with SMARCAL1 contributes towards dysregulated cellular DNA replication.

Discussion

It is now well established that Ad engages with cellular CRLs to stimulate the ubiquitin-mediated degradation of a small number of cellular DDR proteins in order to promote viral replication (1, 2). Typically, E4orf6, serves to recruit CRLs to protein substrates through direct interaction with CRL components Elongin B and Elongin C, whilst E1B-55K through direct interaction with both E4orf6 and protein substrates, recruits cellular proteins to CRLs for polyubiquitylation and proteasome-mediated degradation (1, 2). Using well-established Ad5 and Ad12 mutant viruses we show that Ad likely utilizes this canonical pathway to promote the degradation of the cellular replication protein, SMARCAL1, during infection (Figures 2 and 3). Indeed, treatment with the NAE inhibitor reduced the extent of degradation of SMARCAL1 during infection, suggesting that CRLs contribute to this degradation process.

It was evident during our studies that, prior to its degradation, a higher molecular weight form of SMARCAL1 was observed upon SDS-PAGE (Figure 2). In this regard we used mass spectrometry to establish that SMARCAL1 was phosphorylated on residues S123, S129 and S173 early during both Ad5 and Ad12 infection (Figure 4). S123 and S129 form part of minimal CDK consensus SP motifs and S173, forms part of a consensus ATM/ATR SQE motif. Although all of these residues have been shown previously to be phosphorylated in vivo the biological significance of these phosphorylation events has yet to be determined (28).

Given that S123 and S129 are likely to be phosphorylated by a CDK and S173 is likely phosphorylated by ATR we investigated whether small molecule inhibitors of ATR kinase and CDKs could affect the ability of Ad to promote SMARCAL1 degradation. Significantly,
ATR and CDKs cooperate to promote the Ad-targeted degradation of SMARCAL1 during infection (Figure 5), suggesting that S123, S129 and S173 all contribute towards SMARCAL1 stability in vivo. Although RO-3306 has greater selectivity for CDK1 than CDK2 and CDK4 (33) Ad infection is known to stimulate the activity of all three kinases (34), such that we cannot, at present, state which CDK(s) is/are responsible for phosphorylating SMARCAL1 during Ad infection. We wished to investigate further the role of phosphorylation of these specific residues in the Ad-mediated degradation of SMARCAL1. To this end we made GFP-SMARCAL1 RPE-1 cell lines where S123, S129 and S173 residues were all mutated to A to ablate phosphorylation at these sites. Although we were able to generate clonal cell lines that expressed these mutations, we were unable to undertake these studies as Ad infection results in the transactivation of the CMV promoter that regulates GFP-SMARCAL1 expression (data not shown).

We were however, able to use the wt GFP-SMARCAL1 and GFP-SMARCAL1 phosphomutant RPE-1 cell lines to address the role of SMARCAL1 phosphorylation in the recruitment of SMARCAL1 to VRCs. As such, we determined that ATR and CDKs, although not essential, contributed to some extent in the recruitment of SMARCAL1 to VRCs during infection (Figure 6). Moreover, using a GFP-SMARCAL1 species lacking its N-terminal RPA interaction motif we were also able to establish that SMARCAL1 association with RPA is a major determinant in SMARCAL1 recruitment to VRCs (Figure 6). SMARCAL1 was initially characterized as an RPA-interacting protein, and its recruitment to replication forks and sites of DNA damage was shown to be dependent upon its interaction with RPA (21-25). More recent studies have determined that RPA in addition to its ability to control SMARCAL1 localization also confers substrate specificity and regulates SMARCAL1 fork-remodelling reactions through the orientation of its high affinity DNA-binding domains (35).
RPA is a single-stranded DNA binding protein complex that has long been known to promote large T-antigen-dependent SV40 DNA replication (36). Although RPA has been shown to be recruited to Ad VRCs during infection its precise role in Ad replication is not known (19, 20).

Given that SMARCAL1 is an RPA-binding protein and that most of its activities are controlled by RPA, it is interesting to speculate that any pro-viral RPA functions during Ad infection are not coordinated through the activation of SMARCAL1-dependent remodelling activities. Indeed, as SMARCAL1 is degraded during infection (Figure 2), it is highly likely that SMARCAL1 possesses anti-viral activities. As the mechanism of SV40 DNA replication is well established it would be interesting to determine the requirement for SMARCAL1 in RPA-dependent SV40 DNA replication.

Given the role of SMARCAL1 in cellular DNA replication we investigated the effects of Ad E1B-55K expression on cellular DNA replication. We observed that E1B-55K expression enhanced nascent cellular DNA replication fork speed but, ultimately, E1B-55K expression resulted in increased replication fork stalling (Figure 9). It has been determined previously that loss of SMARCAL1 prevents replication re-start after replication stress, resulting in stalled replication, whilst knockdown of p53 and MRE11, also promote stalled cellular DNA replication (28, 37, 38). More generally, it has been determined that oncogene product expression can enhance replication stress to either increase, or decrease, DNA replication initiation, elongation, fork speed, fork stalling and fork re-start through the modulation of origin firing, replication-transcription collisions, reactive oxygen species, and defective nucleotide metabolism (39). It is plausible therefore that the E1B-55K oncoprotein promotes replication stress in Ad-infected cells through interaction with p53, MRE11, SMARCAL1 and potentially other cellular targets that ultimately results in cellular DNA replication inhibition. Given the known role of E1B-55K in the promotion of late viral mRNA accumulation and the inhibition of cellular mRNA transport, and translation, in the mediation
of host protein shutoff, as well as the proposed role for Ad-mediated protein degradation in mRNA export (40, 41) we postulate that E1B-55K similarly inhibits cellular DNA replication and promotes viral replication through the specific targeting of cellular E1B-55K-interacting proteins for degradation during infection.

Acknowledgements

We would like to thank David Cortez (Vanderbilt University, Nashville, TN) for SMARCAL1 reagents and Thomas Dobner (Heinrich Pette Institute, Hamburg, Germany) for adenovirus 5 mutants. We would also like to thank the BBSRC MIBTP programme for funding for Maria Teresa Tilotta and Simon Davis (BB/M01116X/1; BB/J014532/1) and Jazan and Taibah Universities, Saudi Arabia, for funding Fadi Qashqari and Abeer Albalawi, respectively.

References


**Figure Legends.**

FIG 1. SMARCAL1 is reorganized to viral replication centres during the early stages of Ad infection. A549 cells were either mock-infected (panels i-iii), or infected with 10 pfu/cell of *wt* Ad5 (panels iv-vi) or *wt* Ad12 (panels vii-ix). At 18h post-infection, cells were fixed, permeabilized and co-stained for SMARCAL1 and RPA2. Arrows indicate regions of RPA2/SMARCAL1 co-localization. In all instances images were recorded using a Zeiss LSM510-Meta confocal microscope.

FIG 2. SMARCAL1 is targeted for degradation during Ad infection. A549 cells were either mock-infected or infected with 10 pfu/cell of *wt* Ad5 or *wt* Ad12 and harvested at the appropriate times post-infection. (A) Ad5 cell lysates were then subject to WB for SMARCAL1, p53, E1B-55K, E4orf6 and β-actin. (B) Ad12 cell lysates were subject to WB for SMARCAL1, p53, E1B-55K and β-actin. h.p.i - hours post-infection. Representative of more than three independent experiments.
FIG 3. SMARCAL1 is degraded during Ad infection in an E1B-55K/E4orf6- and CRL-dependent manner. (A) A549 cells were either mock-infected, infected with wt Ad5, or infected with E1B-55K (dl1520), E4orf3 (H5pm4150) or E4orf6 (H5pm4154) deletion viruses. At 24 h and 48 h post-infection cells were harvested and subject to WB for SMARCAL1, p53, E1B-55K, E4orf3, E4orf6 and β-actin. (B) A549 cells were either mock-infected, infected with wt Ad12, or infected with the E1B-55K (dl620) deletion virus. At 24 h and 48 h post-infection cells were harvested and Western blotted for SMARCAL1, p53, E1B-55K, and β-actin. (C and D) A549 cells were either mock-infected or infected with wt Ad5 or wt Ad12, in the absence or presence of 100 nM or 500 nM MLN4924. At 24 h and 48 h post-infection cells were harvested and subject to WB for SMARCAL1, p53, E1B-55K and β-actin. h.p.i - hours post-infection. Representative of three independent experiments.

FIG 4. SMARCAL1 is phosphorylated during the early stages of Ad infection. (A) A549 cells were either mock-infected, treated with MLN4924, or infected with 10 pfu/cell of wt Ad5 or wt Ad12 and harvested at 18 h post-infection. Cells were harvested in IP buffer and subject to immunoprecipitation for SMARCAL1. Anti-SMARCA1 immunoprecipitates collected on protein G-sepharose were treated in the absence, or presence, of λ-phosphatase and then subject to SDS-PAGE and WB for SMARCAL1. (B) SMARCAL1 was immunoprecipitated from mock-infected and wt Ad5 or wt Ad12 infected A549 cells 18 h post-infection, and separated by SDS-PAGE. Protein bands excised from the gel were subject to trypsinization and mass spectrometric analysis. Identified SMARCAL1 phosphorylated peptides from Ad-infected cells are presented. (C) S123, S129 and S173 are conserved between primates but less well conserved in lower mammals. SMARCAL1 primary sequences from a number of species were aligned using CLUSTAL Omega. Shaded areas indicate conserved residues.
FIG 5. ATR kinase and CDKs promote SMARCAL1 degradation following Ad5 and Ad12 infection. A549 cells were either mock-infected or infected with 10 pfu/cell of wt Ad5 (A and C) or wt Ad12 (B and D). Cells were then incubated in the absence or presence of ATR inhibitor (AZD6738 (ATRi), 1 µM; A and B) or ATR and CDK inhibitors (AZD6738, 1 µM and RO-3306 (CDKi), 9 µM; C and D) and harvested at the appropriate times post-infection. Cell lysates were then separated by SDS-PAGE and subject to WB for SMARCAL1, p53, E1B-55K, and β-actin. h.p.i - hours post-infection. Representative of three independent experiments.

FIG 6. SMARCAL1 is recruited to VRCs in an RPA-dependent, and ATR and CDK -dependent, manner. (A) Microscopic images depicting the cellular localization of wt GFP-SMARCAL1, GFP-SMARCAL1-ΔP and GFP-SMARCAL1-ΔRPA in mock-infected (panels i-iii), wt Ad5-infected (panels iv-vi) or wt Ad12-infected cells (panels vii-ix) 18 h post-infection. (B) Bar graph (+/- S.E.M.) showing the % of GFP-labelled cells that are recruited to VRCs following Ad5 or Ad12 infection. n=3 (300 cells per experiment; 900 cells in total). Only those cells that exhibited clear GFP-SMARCAL1 structures in Ad-infected cells, comparable to the known architecture of VRCs at different stages of infection, were counted as VRC positive. Data presented was subjected to ANOVA two-tailed t-test. Significance testing for difference in recruitment of GFP-SMARCAL1-ΔP to VRCs relative to wt GFP-SMARCAL1 following Ad5 infection: p = 0.0065 (**); difference in recruitment of GFP-SMARCAL1-ΔRPA to VRCs relative to wt GFP-SMARCAL1 following Ad5 infection: p = 8.8E-05 (****); difference in recruitment of GFP-SMARCAL1-ΔP to VRCs relative to wt GFP-SMARCAL1 following Ad12 infection: p = 0.04 (*); difference in recruitment of GFP-SMARCAL1-ΔRPA to VRCs relative to wt GFP-SMARCAL1 following Ad5 infection: p = 0.002 (**).
FIG 7. Ad E1B-55K associates with SMARCAL1 in Ad-transformed cells. (A) Ad E1B-55K and SMARCAL1 were immunoprecipitated from Ad5 HEK 293 cells (A) and Ad12 HER2 cells (B) and subject to WB for E1B-55K and SMARCAL1. IgG, immunoglobulin control IP.

FIG 8. Generation and characterization of TET-inducible Ad5 and Ad12 E1B-55K FlpIn U2OS cells. FlpIn U2OS cells were transfected with Ad5 E1B-55K and Ad12 E1B-55K pcDNA5/FRT/TO plasmids and the recombination plasmid, pOG44. Cells were incubated in selection medium containing hygromycin (200 μg/ml). Individual colonies were isolated, expanded and treated with 0.1 μg/ml doxycycline. 24 h post-induction cell lysates were harvested, separated by SDS-PAGE and subject to WB analysis for Ad5 and Ad12 E1B-55K. WB analyses were also performed to gauge the levels of SMARCAL1, p53, MRE11 and β-actin for Ad5 E1B-55K, and Ad12 E1B-55K, FlpIn U2OS cells, respectively. Representative of more than three independent experiments.

FIG 9. Ad5 and Ad12 E1B-55K modulate cellular DNA replication rates and promote replication fork stalling. Uninduced, and doxycycline-induced, Ad5 and Ad12 E1B-55K FlpIn U2OS cells were labelled with 25 μM CldU and 250 μM IdU for 20 min each. DNA fibre spreads were then prepared and denatured with 2.5 M HCl. DNA fibres were labelled with the appropriate primary and secondary antibodies and visualised using a Nikon E600 microscope. (A and B) Representative DNA spreads (+/- Ad5 or Ad12 E1B-55K) are shown indicating the mean fork speeds; CldU and IdU fork lengths were quantified and presented as dot plots (+/- S.D.) with the mean fork speed shown as a red bar. n = 3 (Total fibres analysed: Ad5 mock = 347; + Ad5 E1B-55K = 368; Ad12 mock = 370; + Ad12 E1B-55K = 364). (C) % stalled forks (CldU-only labelled forks) were quantified and presented as a bar chart +/- S.D. In all instances data presented was subjected to ANOVA two-tailed t-test; + Ad5 E1B-55K CldU tract length relative to mock CldU tract length, p = 4.8E-20 (**); + Ad5 E1B-55K CldU/IdU ratio relative to mock CldU tract length, p = 9.44E-45 (****); + Ad12 E1B-55K CldU/IdU ratio relative to mock CldU tract length, p = 9.44E-45 (****); + Ad12 E1B-55K CldU tract length relative to mock CldU tract length, p = 4.8E-20 (**); + Ad12 E1B-55K CldU/IdU ratio relative to mock CldU tract length, p = 9.44E-45 (****); + Ad12 E1B-55K CldU tract length relative to mock CldU tract length, p = 4.8E-20 (**); + Ad12 E1B-55K CldU/IdU ratio relative to mock CldU tract length, p = 9.44E-45 (****); + Ad12 E1B-55K CldU tract length relative to mock CldU tract length, p = 4.8E-20 (**); + Ad12 E1B-55K CldU/IdU ratio relative to mock CldU tract length, p = 9.44E-45 (****); + Ad12 E1B-55K CldU tract length relative to mock CldU tract length, p = 4.8E-20 (**); + Ad12 E1B-55K CldU/IdU ratio relative to mock CldU tract length, p = 9.44E-45 (****); + Ad12 E1B-55K CldU tract length relative to mock CldU tract length, p = 4.8E-20 (**); + Ad12 E1B-55K CldU/IdU ratio relative to mock CldU tract length, p = 9.44E-45 (****); + Ad12 E1B-55K CldU tract length relative to mock CldU tract length, p = 4.8E-20 (**); + Ad12 E1B-55K CldU/IdU ratio relative to mock CldU tract length, p = 9.44E-45 (****); + Ad12 E1B-55K CldU tract length relative to mock CldU tract length, p = 4.8E-20 (**); + Ad12 E1B-55K CldU/IdU ratio relative to mock CldU tract length, p = 9.44E-45 (****); + Ad12 E1B-55K CldU tract length relative to mock CldU tract length, p = 4.8E-20 (**); + Ad12 E1B-55K CldU/IdU ratio relative to mock CldU tract length, p = 9.44E-45 (****); + Ad12 E1B-55K CldU tract length relative to mock CldU tract length, p = 4.8E-20 (**); + Ad12 E1B-55K CldU/IdU ratio relative to mock CldU tract length, p = 9.44E-45 (****); + Ad12 E1B-55K CldU tract length relative to mock CldU tract length, p = 4.8E-20 (**); + Ad12 E1B-55K CldU/IdU ratio relative to mock CldU tract length, p = 9.44E-45 (****); + Ad12 E1B-55K CldU tract length relative to mock CldU tract length, p = 4.8E-20 (**); + Ad12 E1B-55K CldU/IdU ratio relative to mock CldU tract length, p = 9.44E-45 (****); + Ad12 E1B-55K CldU tract length relative to mock CldU tract length, p = 4.8E-20 (**); + Ad12 E1B-55K CldU/IdU ratio relative to mock CldU tract length, p = 9.44E-45 (****); + Ad12 E1B-55K CldU tract length relative to mock CldU tract length, p = 4.8E-20 (**); + Ad12 E1B-55K CldU/IdU ratio relative to mock CldU tract length, p = 9.44E-45 (****); + Ad12 E1B-55K CldU tract length relative to mock CldU tract length, p = 4.8E-20 (**); + Ad12 E1B-55K CldU/IdU ratio relative to mock CldU tract length, p = 9.44E-45 (****); + Ad12 E1B-55K CldU tract length relative to mock CldU tract length, p = 4.8E-20 (**); + Ad12 E1B-55K CldU/IdU ratio relative to mock CldU tract length, p = 9.44E-45 (****); + Ad12 E1B-55K CldU tract length relative to mock CldU tract length, p = 4.8E-20 (**); + Ad12 E1B-55K CldU/IdU ratio relative to mock CldU tract length, p = 9.44E-45 (****); + Ad12 E1B-55K CldU tract length relative to mock CldU tract length, p = 4.8E-20 (**); + Ad12 E1B-55K CldU/IdU ratio relative to mock CldU tract length, p = 9.44E-45 (****); + Ad12 E1B-55K CldU tract length relative to mock CldU tract length, p = 4.8E-20 (**); + Ad12 E1B-55K CldU/IdU ratio relative to mock CldU tract length, p = 9.44E-45 (****); + Ad12 E1B-55K CldU tract length relative to mock CldU tract length, p = 4.8E-20 (**); + Ad12 E1B-55K CldU/IdU ratio relative to mock CldU tract length, p = 9.44E-45 (****); + Ad12 E1B-55K CldU tract length relative to mock CldU tract length, p = 4.8E-20 (**); + Ad12 E1B-55K CldU/IdU ratio relative to mock CldU tract length, p = 9.44E-45 (****); + Ad12 E1B-55K CldU tract length relative to mock CldU tract length, p = 4.8E-20 (**); + Ad12 E1B-55K CldU/IdU ratio relative to mock CldU tract length, p = 9.44E-45 (****); + Ad12 E1B-55K CldU tract length relative to mock CldU tract length, p = 4.8E-20 (**); + Ad12 E1B-55K CldU/IdU ratio relative to mock CldU tract length, p = 9.44E-45 (****); + Ad12 E1B-55K CldU tract length relative to mock CldU tract length, p = 4.8E-20 (**); + Ad12 E1B-
55K CldU tract length relative to mock CldU tract length, $p = 1.29\times 10^{-32}$ (****); + Ad12 E1B-

55K CldU/IdU ratio relative to mock CldU tract length, $p = 6.32\times 10^{-61}$ (****); ns = not

significant. Stalled forks: Ad5 E1B-55K relative to mock, $p= 0.009$ (**); Ad12 E1B-55K relative to mock, $p=0.002$ (**).
Figure 2
Figure 3
Figure 4

**A**

![Image showing p-SMARCAL1 and SMARCAL1](image)

**B**

<table>
<thead>
<tr>
<th>Sequence</th>
<th>Modifications</th>
<th>Phosphoresidue</th>
</tr>
</thead>
<tbody>
<tr>
<td>SQmALTGlsPPLAQsPPEVPK</td>
<td>M3(Oxidation); S9(Phospho) y+; S15(Phospho) y+</td>
<td>S123; S129</td>
</tr>
<tr>
<td>SQmALTGlsPPLAQsPPEVPK</td>
<td>S9(Phospho) y+; S15(Phospho) y+</td>
<td>S123; S129</td>
</tr>
<tr>
<td>SQmALTGlsPPLAQsPPEVPK</td>
<td>S15(Phospho) y+, b+</td>
<td>S129</td>
</tr>
<tr>
<td>SsQETPAHSSGQPPR</td>
<td>S2(Phospho)</td>
<td>S173</td>
</tr>
</tbody>
</table>

**C**

<table>
<thead>
<tr>
<th>Species</th>
<th>Sequence</th>
<th>Phosphoresidue</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUMAN</td>
<td>LTGISPLAQSPPEVPKQQLSLELGQHAGASPEIRFTPFANPTHKPLAKPKSSQETPAH</td>
<td>179</td>
</tr>
<tr>
<td>GORILLA</td>
<td>LTGISPLAQSPPEVPKQQLSLELGQHAGASPEIRFTPFANPTHKPLAEAKSSQETPAH</td>
<td>179</td>
</tr>
<tr>
<td>CHIMPANZEE</td>
<td>LTGISPLAQSPPEVPKQQLSLELGQHAGASPEIRFTPFANPTHKPLAKPKSSQETPAH</td>
<td>179</td>
</tr>
<tr>
<td>RH. MONKEY</td>
<td>LTGISPLAQSPPEVPKQQLSLELGQHAGAEASPEIRFTPFAHPTHEPLAKAKNSQETPAH</td>
<td>179</td>
</tr>
<tr>
<td>ORANGUTAN</td>
<td>LTGISPLAQSPPEVPKQQLSLELGQHAGASPEIRFTPFANPTHPLAKAKSSQETPAH</td>
<td>179</td>
</tr>
<tr>
<td>DOG</td>
<td>LTGISPLAQSPPEVPQCGLCALGQAGHLQASHAERSTTPANFTPELSHAKSKFQTPAS</td>
<td>185</td>
</tr>
<tr>
<td>MOUSE</td>
<td>SPFGASNQPLLGYKSSGQPATW---------DTGAS</td>
<td>146</td>
</tr>
</tbody>
</table>
Figure 5
Figure 6
Figure 7
Figure 8

<table>
<thead>
<tr>
<th>Ad5</th>
<th>Ad12</th>
</tr>
</thead>
<tbody>
<tr>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

- β-actin
- Ad12 E1B-55K
- Ad5 E1B-55K
- MRE11
- p53
- SMARCAL1
Figure 9